DOV receives notice of patent allowance for crystalline form of novel analgesic, bicifadine

By Lisa Kerner

Erie, Pa., April 11 - DOV Pharmaceutical, Inc. said the U.S. Patent and Trademark Office issued a Notice of Allowance for its patent application covering a new polymorphic, or crystalline, form of its proprietary compound bicifadine, a novel analgesic.

The patent, expected to be issued in the next several weeks, would have a term that runs through at least 2024 for this form of bicifadine, the same form used in DOV's clinical trials and bicifadine development program, according to a company news release.

"We believe this patent will further increase bicifadine's significant commercial potential and marks an important milestone in the compound's development," chief executive officer and president Dr. Leslie Hudson said in the release.

"DOV has additional formulation, process and novel use patent filings pending for bicifadine and we are committed to further enhancing the intellectual property portfolio to protect the market for this important new analgesic."

The company said bicifadine is being evaluated in three phase 3 clinical trials in chronic low back pain patients, one phase 2 trial in patients with neuropathic pain and one phase 2 trial in patients with osteoarthritis of the hip or knee.

DOV expects to file its first New Drug Application for bicifadine in chronic pain in the first half of 2007.

Located in Hackensack, N.J., DOV discovers, acquires, develops and commercializes novel drug candidates for central nervous system disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.